Explore how adjuvant osimertinib aids in detecting molecular residual disease in resected EGFR-mutated NSCLC, offering ...
AstraZeneca declined to comment without detailed clinical data on claims by Chinese makers of a competing experimental lung cancer drug.
A new Yale study has found evidence to support the value of a tool that measures the presence of cancer -derived molecules in ...
In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that ...
Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines ...
SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...
DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback